Searched over 200M research papers
10 papers analyzed
These studies suggest that blood tests can detect various types of cancer with varying degrees of accuracy and specificity, potentially improving early detection and outcomes.
13 papers analyzed
20 papers analyzed
Blood tests have emerged as a promising tool for the early detection of cancer. These tests can identify molecular markers associated with cancer, offering a non-invasive method to detect the disease before symptoms appear. This article synthesizes recent research on the efficacy and accuracy of blood tests in detecting various types of cancer.
One of the most notable advancements in blood-based cancer detection is the development of CancerSEEK. This test evaluates eight circulating protein biomarkers and tumor-specific mutations in circulating DNA to detect eight common cancer types, including ovarian, liver, stomach, pancreatic, esophageal, colorectal, lung, and breast cancers. In a study involving 1,005 patients with non-metastatic cancers, CancerSEEK demonstrated a sensitivity range of 69% to 98% and a specificity greater than 99%. This high specificity means that the test has a low false-positive rate, making it a reliable tool for early cancer detection.
In addition to detecting cancer, CancerSEEK can also localize the cancer to a small number of anatomical sites in a median of 83% of patients, which is crucial for guiding subsequent diagnostic and therapeutic interventions.
Another study explored the feasibility of combining a multicancer blood test with positron emission tomography-computed tomography (PET-CT) imaging. This approach was tested on 10,006 women with no prior history of cancer. The blood test detected 26 cancers, and PET-CT imaging confirmed and localized these cancers, leading to surgical removal in nine cases. The study found that the combination of blood testing and PET-CT had a specificity of 99.6% and a positive predictive value of 28.3%. This combination minimizes unnecessary follow-up procedures and enhances the accuracy of cancer detection.
The PanSeer test, which detects cancer based on circulating tumor DNA methylation, has shown the potential to identify cancer up to four years before conventional diagnosis. In a study involving 605 asymptomatic individuals, PanSeer detected five common types of cancer with a sensitivity of 95% and a specificity of 96%. These results suggest that PanSeer could significantly improve early cancer detection, potentially reducing cancer mortality by identifying the disease at a more treatable stage.
A systematic review and meta-analysis examined the accuracy of tumor origin detection using cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) tests. The review found that the accuracy of predicting the tissue of origin was 79%, with colorectal cancers showing the highest accuracy and liver and bile duct cancers the lowest . This ability to accurately localize the tumor origin is essential for guiding appropriate treatment strategies.
Several studies have focused on blood markers for the early detection of colorectal cancer (CRC). A systematic review identified multiple promising markers, including methylated SEPT9 DNA, which showed sensitivities ranging from 48.2% to 95.6% and specificities from 80% to 98.9%. Combining these markers with other tests, such as the fecal immunochemical test (FIT), can further improve detection rates.
Blood tests have shown significant promise in the early detection of various cancers. Tests like CancerSEEK and PanSeer, along with the integration of imaging techniques like PET-CT, offer high sensitivity and specificity, making them valuable tools in cancer screening. While further research is needed to refine these tests and expand their applicability, the current evidence supports their potential to improve early cancer detection and patient outcomes.
Most relevant research papers on this topic